ClinicalTrials.gg
RecruitingNCT05388487Updated Jan 16, 2024

Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

A Phase 1 interventional study of HF1K16 /Arm 45 mg/m² and HF1K16 /Arm 90 mg/m² in Solid Tumor, Adult, sponsored by HighField Biopharmaceuticals Corporation. Recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-16.

Sponsored by HighField Biopharmaceuticals Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL) and for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs).

Read the detailed description

Myeloid Derived Suppressor Cells (MDSCs) play important roles in constituting the immune suppressive environment promoting cancer development and progression. While previous studies had shown that all-trans retinoic acid (ATRA) could induce MDSC differentiation and maturation, the very poor solubility and fast metabolism of the drug limited its applications as an immune-modulator for cancer immunotherapy

HF1K16 is an investigational pegylated liposome formulation with great ATRA dose loading capacity and sustained drug release property. In preclinical studies, HF1K16 was shown to be able to remodel the host systemic immune homeostasis as well as modify tumor microenvironment (TME). It promotes MDSCs maturation into DCs and facilitates immune responses against cancer cells.

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

HighField Biopharmaceuticals Corporation is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide the test of in writing.
  2. Male or female, age > 18 years and \< = 75 years.
  3. The subjects had to be diagnosed by histology and/or cytology with locally advanced or solid tumor. There is no effective standard of care or the patient is intolerant to the standard therapy.

    Cohort 5: The subjects must be diagnosed with glioma by histology, and the disease has or progressed after previous treatment, and there is no effective standard treatment or the subject is intolerant to standard treatment.

  4. According to the definition of 1.1, participants must have at least one .

    Cohort 5: at least one lesion that can be measured in two dimensions is required ( RANO criteria).

  5. Eastern group () tumor physical state to 0 or 1. Cohort 5: According to physical fitness score ≥ 60.
  6. Expected lifetime > 12 weeks.
  7. Men or women of childbearing age must agree to adopt effective after signing the informed consent form until 180 days after the end of the study. Premenopausal women or those within 2 years after menopause are included.

Exclusion criteria

Exclusion Criteria:

  1. Patients received systemic antitumor therapy, including chemotherapy, radiotherapy, biologic therapy, endocrine therapy, or immunotherapy within 3 weeks prior to the first dose, except for the following: Nitrosoureas or mitomycin C within 6 weeks; Oral fluorouracils and small molecule drugs within 2 weeks or within 5 half-life periods of the drug (whichever is longer); Antitumour traditional Chinese medicine within 2 weeks.
  2. Adverse effects of previous anti-tumor therapy have not recovered to 5.0 grade rating of ≤ grade 1 (except for toxicity judged by the investigator be of no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, etc.)
  3. Patients received other unlisted clinical trial drugs or treatments within 28 days prior to the first dose.
  4. Taken vitamin A or any vitamin A derivatives within 7 days prior to the first dose.
  5. Past history of deep vein thrombosis or pulmonary embolism.
  6. Evidence that there is poor control of thyroid diseases, or diseases of the retina.
  7. Patients have symptomatic central nervous system (CNS) , meningeal metastases, or a primary CNS tumor that is associated with progressive neurological symptoms. Except that the are shown to be stable judged by imaging examination within 4 weeks.

    Cohort 5: The above criteria do not apply to the fifth cohort. The fifth cohort allowed inhaled or topical , or hormone therapy at physiological replacement doses due to adrenal insufficiency; short-term (≤7 days) corticosteroids were allowed for prophylaxis (eg, contrast media allergy) or treatment of non- conditions ( For example, delayed-type reactions caused by exposure to allergens); systemic corticosteroids (≥10 mg/day prednisone, or other equivalent corticosteroids) for 7 consecutive days within 14 days of the first dose are not allowed or therapy.

  8. Evidences of serious or uncontrolled systemic disease (for example: instability or decompensated respiratory disease, liver or kidney disease)
  9. Serious liver and kidney function damage;
  10. Has clinical significance of cardiovascular disease;
  11. Have known immune inhibitory disease or (HIV) infection.
  12. Patients with severe osteoporosis or with bone metastases with serum 25-hydroxyvitamin D assay values less than 50 nmol/L.
  13. Active hepatitis (: HBsAg-positive and HBV-DNA ≥ 500 cps/mL or 200 IU/mLL; -positive).
  14. Persons with known hypersensitivity to any of the active ingredients or or a history of atopic allergic reactions.
  15. The pregnancy test positive (blood beta human chorionic gonadotropin - HCG [B] test positive) or lactationWomen.
  16. Researchers believe that patients with combined disease may affect the compliance.
  17. Participants not willing to or fail to follow the procedure.
  18. Cohort 5: Brain MRI not available.
  19. Cohort 5: uncontrolled epilepsy.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Dose escalation cohort 1: HF1K16 given QOD at 45 mg/m²

    The first dosing group (45 mg/m²) will include a sentinel subject receiving one dose followed by a 7-day safety evaluation interval. Three or more subjects will receive 7 doses of HF1K16 QOD at 45 mg/m2 per cycle of 21 days.

    Drug: HF1K16 /Arm 45 mg/m²

  • Experimental
    Dose escalation cohort 2: Oral ATRA followed by HF1K16 QOD at 90 mg/m²

    The second dosing group will receive oral ATRA at 45mg/m², and three days later HF1K16 QOD at 90 mg/m2 for 7 times per cycle of 21 days.

    Drug: HF1K16 /Arm 90 mg/m²

  • Experimental
    Dose escalation cohort 3: HF1K16 QOD at 120 mg/m²

    The cohort 3 will receive 7 doses of HF1K16 QOD at 120 mg/m² per cycle of 21 days.

    Drug: HF1K16 /Arm 120 mg/m²

  • Experimental
    Dose escalation cohort 4: HF1K16 QOD at 160 mg/m²

    The cohort 4 will receive 7 doses of HF1K16 QOD at 160 mg/m² per cycle of 21 days.

    Drug: HF1K16 /Arm 160 mg/m²

  • Experimental
    Dose escalation cohort 5: HF1K16 QOD at 120mg or180 mg

    The cohort 5 will receive 7 doses of HF1K16 QOD at 120 mg or 180mg per cycle of 21 days.

    Drug: HF1K16 /Arm 120 mg or 180 mg

Interventions

  • DrugHF1K16 /Arm 45 mg/m²

    HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

  • DrugHF1K16 /Arm 90 mg/m²

    HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

  • DrugHF1K16 /Arm 120 mg/m²

    HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

  • DrugHF1K16 /Arm 160 mg/m²

    HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

  • DrugHF1K16 /Arm 120 mg or 180 mg

    HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)

    Time frame: 30 days after administration

  2. Incidence of dose-limiting toxicities(DLT)

    Observe the dose limiting toxicity, and Incidence of dose-limiting toxicities(DLT) will be assessed

    Time frame: 21 days after administration

  3. Respiration rate of Vital Signs by stethoscope

    Changes from baseline for respiration rate in breaths per minute of Vital Signs

    Time frame: 30 days after administration

  4. Red blood cell count in whole blood sample

    Changes from baseline for Red blood cell count in whole blood in10\^9 /L

    Time frame: 30 days after administration

  5. Ventricular rate of ECG

    Changes from baseline for ventricular rate in beats per minute

    Time frame: 30 days after administration

  6. Respiration rate in mg μl/h·g of ECG

    Changes from baseline for respiration rate in mg μl/h·g

    Time frame: 30 days after administration

  7. Heart rate in beats per minute in beats per minute of ECG

    Changes from baseline for heart rate in beats per minute

    Time frame: 30 days after administration

  8. Blood pressure by sphygmomanometer

    Changes from baseline for blood pressure in mmHg, both systolic and diastolic pressures will be assessed.

    Time frame: 30 days after administration

  9. Body temperature by thermometer

    Changes from baseline for body temperature in Celsius degree

    Time frame: 30 days after administration

  10. White blood cell count in whole blood sample

    Changes from baseline for white blood cell count in whole blood in 10\^9 /L

    Time frame: 30 days after administration

  11. Neutrophil count in whole blood sample

    Changes from baseline for neutrophil count in whole blood in 10\^9 /L

    Time frame: 30 days after administration

  12. Hemoglobin concentration in g/dL in whole blood sample

    Changes from baseline for hemoglobin concentration in g/dL in whole blood

    Time frame: 30 days after administration

  13. Prothrombin time in whole blood sample

    Changes from baseline for Prothrombin time in s

    Time frame: 30 days after administration

  14. International standardized ratio in whole blood sample

    Changes from baseline for international standardized ratio

    Time frame: 30 days after administration

  15. International sensitivity index in whole blood sample

    Changes from baseline for international sensitivity index

    Time frame: 30 days after administration

  16. Activated partial thromboplastin time in whole blood sample

    Changes from baseline for activated partial thromboplastin time in s

    Time frame: 30 days after administration

  17. Total bilirubin concentration in whole blood sample

    Changes from baseline for total bilirubin concentration in μmol/L

    Time frame: 30 days after administration

  18. ALT concentration in whole blood sample

    Changes from baseline for alanine aminotransferase(ALT) concentration in U/L

    Time frame: 30 days after administration

  19. AST concentration in whole blood sample

    Changes from baseline for aspartate aminotransferase(AST) concentration in U/L

    Time frame: 30 days after administration

  20. Total protein concentration in whole blood sample

    Changes from baseline for total protein concentration in g/L

    Time frame: 30 days after administration

  21. Urea concentration in whole blood sample

    Changes from baseline for urea concentration in mmol/L

    Time frame: 30 days after administration

  22. Creatinine concentration in whole blood sample

    Changes from baseline for creatinine concentration in μmol/L

    Time frame: 30 days after administration

  23. Total cholesterol concentration in whole blood sample

    Changes from baseline for total cholesterol concentration in mmol/L

    Time frame: 30 days after administration

  24. Triglycerides concentration in whole blood sample

    Changes from baseline for triglycerides concentration in mmol/L

    Time frame: 30 days after administration

  25. HDL-C in whole blood sample

    Changes from baseline for high density lipoprotein cholesterol (HDL-C) in mmol/L

    Time frame: 30 days after administration

  26. LDL-C in whole blood sample

    Changes from baseline for low density lipoprotein cholesterol (LDL-C) in mmol/L

    Time frame: 30 days after administration

  27. PR interval by ECG

    Changes from baseline for PR interval in ms of ECG

    Time frame: 30 days after administration

  28. QRS by ECG

    Changes from baseline for QRS in ms of ECG

    Time frame: 30 days after administration

  29. QT by ECG

    Changes from baseline for QT in ms of ECG

    Time frame: 30 days after administration

  30. QTc by ECG

    Changes from baseline for QTc in ms of ECG

    Time frame: 30 days after administration

  31. Cohort 5: Determination of overall response rate (ORR) according to RANO criteria

    ORR is defined as the proportion of participants with complete response or partial response (CR+PR)

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks

  32. Cohort 5: Duration of response (DOR)

    DOR, defined as the time between the start of the subject's first assessment of CR or PR and the first assessment of PD or death from any cause, according to RANO criteria by the investigator

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks

  33. Cohort 5: disease control rate (DCR)

    DCR , defined as the proportion of subjects with a best overall response of CR, PR, or SD in the study as assessed by the investigator according to RANO criteria

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks

  34. Cohort 5: progression-free survival (PFS).

    PFS, defined as the time between the subject's first dose and the onset of (any aspect of) tumor progression or death from any cause

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks

Secondary outcomes

  1. HF1K16 pharmacokinetic parameters with Cmax

    Maximum plasma concentration (Cmax) after administration of HF1K16

    Time frame: Up to 48 hours postdose

  2. the overall response rate(ORR) of HF1K16

    ORR is defined as the proportion of participants with complete response or partial response (CR+PR)

    Time frame: Once every six weeks in the first year, then once every 12 weeks afterwards through study completion, an average of 1 year

  3. Peripheral blood mononuclear cells by whole blood sample

    Assessing peripheral blood mononuclear cells after dose in cells/mL

    Time frame: Before injection on Day1,7,13, 21 in each cycle(each cycle is 21 days)

  4. AUC48h by plasma concentration of whole blood sample

    Area under plasma concentration -time curve from 0 time ot 48 h(AUC0-48) after dose

    Time frame: Up to 48 hours postdose

  5. Tmax by plasma concentration of whole blood sample

    Peak time (Tmax) after dose

    Time frame: Up to 48hours postdose

  6. T1/2 by plasma concentration of whole blood sample

    Elimination half-life (T1/2) after dose

    Time frame: Up to 48hours postdose

  7. CL by plasma concentration of whole blood sample

    Clearance (CL) after dose

    Time frame: Up to 48 hours postdose

  8. Vd by plasma concentration of whole blood sample

    Volume of distribution(Vd) after dose

    Time frame: Up to 48 hours postdose

  9. AUClast by plasma concentration of whole blood sample

    Ratios of geometric means of AUClast (Area under the plasma concentration-time curve from zero to time of last quantifiable concentration) after dose

    Time frame: Up to 48 hours postdose

  10. Cohort 5: To assess the changes in MDSC after HF1K16 treatment, including changes in MDSC number

    Assessing peripheral blood mononuclear cells after dose in cells/mL

    Time frame: Before injection on Day1 in each cycle(each cycle is 21 days)

  11. Cohort 5: Incidence of Adverse Events

    Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)

    Time frame: after administration

  12. Cohort 5: To assess the changes in MDSC after HF1K16 treatment, including changes in MDSC phenotype

    Assessment of MDSC phenotype in peripheral blood after drug administration

    Time frame: Before injection on Day1 in each cycle(each cycle is 21 days)

07

Study locations

6 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Apr 2025, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 24, 2022
StartActual
Feb 16, 2022
Primary completionEst.
Apr 2025
CompletionEst.
Nov 2025
Last update
Jan 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05388487
Lead sponsor
HighField Biopharmaceuticals Corporation
Collaborators
Tigermed Consulting Co., Ltd
Responsible party
Sponsor
First posted
May 24, 2022
Start date
Feb 16, 2022
Primary completion
Apr 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Jan 16, 2024

Study contacts

Jinsong Wu, MD
principal investigator · Huashan Hospital Shanghai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion